Essex D. Mitchell Sells 24,856 Shares of Hologic, Inc. (NASDAQ:HOLX) Stock

Hologic, Inc. (NASDAQ:HOLX) COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Hologic Price Performance

Shares of HOLX stock opened at $75.34 on Friday. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The firm has a market capitalization of $17.10 billion, a price-to-earnings ratio of 22.62, a PEG ratio of 2.42 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock’s 50-day simple moving average is $79.81 and its 200-day simple moving average is $78.54.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp lifted its holdings in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the period. FMR LLC lifted its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after purchasing an additional 195,285 shares during the period. Finally, Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent research reports. Evercore ISI lifted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Leerink Partners decreased their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Raymond James lifted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Mizuho cut their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.